Nath Bio-Genes India Q3FY22 net profit at Rs. 2.80 crores

Nath Bio-Genes (India) Limited has reported Standalone financial results for the period ended December 31, 2021.

Financial Results (Q3 FY2022) - QoQ Comparison

The company has reported total income of Rs. 21.9396 crores during the period ended December 31, 2021 as compared to Rs. 15.2369 crores during the period ended September 30, 2021.

The company has posted net profit / (loss) of Rs. 2.8075 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 1.2306 crores for the period ended September 30, 2021.

The company has reported EPS of Rs. 1.48 for the period ended December 31, 2021 as compared to Rs. 0.65 for the period ended September 30, 2021.

Financials	Q3 FY2022	Q2 FY2022	% Change
Total Income	₹ 21.9396 crs	₹15.2369 crs	43.99%
Net Profit	₹2.8075 crs	₹1.2306 crs	128.14%
EPS	₹1.48	₹0.65	127.69%

Financial Results (Q3 FY2022) - YoY Comparison

The company has reported total income of Rs. 21.9396 crores during the period ended December 31, 2021 as compared to Rs.36.9586 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.2.8075 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.4.2474 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.1.48 for the period ended December 31, 2021 as compared to Rs.2.23 for the period ended December 31, 2020.

Financials	Q3 FY2022	Q3 FY2021	% Change
Total Income	₹ 21.9396 crs	₹36.9586 crs	-40.64%
Net Profit	₹2.8075 crs	₹4.2474 crs	-33.90%
EPS	₹1.48	₹2.23	-33.63%

Financial Results (9 Months Ended FY2022) - YoY Comparison

The company has reported total income of Rs.252.2794 crores during the 9 Months period ended December 31, 2021 as compared to Rs.254.3203 crores during the 9 Months period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.48.9497 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.48.5187 crores for the 9 Months period ended December 31, 2020.

The company has reported EPS of Rs.25.76 for the 9 Months period ended December 31, 2021 as compared to Rs.25.53 for the 9 Months period ended December 31, 2020.

Financials	9 Months Ended FY2022	9 Months Ended FY2021	% Change
Total Income	₹252.2794 crs	₹254.3203 crs	-0.80%
Net Profit	₹48.9497 crs	₹48.5187 crs	0.89%
EPS	₹25.76	₹25.53	0.90%

Shares of Nath Bio-Genes (India) Limited was last trading in BSE at Rs. 243.10 as compared to the previous close of Rs. 245.75. The total number of shares traded during the day was 4624 in over 498 trades.

The stock hit an intraday high of Rs. 252.30 and intraday low of 241.00. The net turnover during the day was Rs. 1142185.00.

Source : Equity Bulls

Keywords

NathBioGenesIndia Q3FY22 9MFY22 ResultUpdate